Anti-COVID-19 2-DG drug developed by DRDO was first studied by Patanjali, claims Acharya Balkrishna

New Delhi: 2-deoxy-D-glucose (2-DG), the anti-COVID-19 drug that

has been developed by Defence Research and Development Organization (DRDO)

and been given an emergency use nod by Drugs Controller General of India’s (DCGI),

was first studied by Patanjali researchers, claimed Acharya Balkrishna.

Also Read Story

In New Delhi seat, ex CM vs two sons of ex CMs; Kejriwal vs Dikshit vs Verma

Rohit Sharma stubborn, says ‘pen, mic & laptop’ cant decide his retirement

Indian cricketer Yuzvendra Chahal, wife Dhanashree Verma headed for divorce

Sydney Test: Pant’s 29-ball fifty gives India edge